AstraZeneca is planning to file for approval of anifrolumab in systemic lupus erythematosus in the second half of next year. The Big Pharma is confident data generated across mid- and late-phase trials show the anti-IFNAR1 antibody works despite a pivotal study missing its primary goal.
